Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s privacy ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ offer for the DNA-testing company in a bankruptcy auction.

The DNA testing company faced major hurdles in the past year, including a data breach and a failed take-private attempt by ...

23andMe was once a high-flying biotech firm. It collected a trove of DNA data on millions of its customers, and then it went bust. The fate of that data has been at the center of a legal battle over ...

Anne Wojcicki’s bid to buy 23andMe, the genetic testing company she co-founded nearly 20 years ago, has received the court greenlight. That means Wojcicki’s nonprofit TTAM Research Institute will ...

Genetic testing company 23andMe laid off 100 employees on Jan. 23 due to decreasing sales of its direct-to-consumer DNA test kits, CNBC reports. The layoffs, which affect about 14 percent of the ...

Direct-to-consumer genetic testing now a booming industry—and it’s easy to see why. A simple swap of the inside of your mouth can provide you with insights into your ethnicity, health, and long-lost ...

(Reuters) -Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy ...